Cargando…
Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy
Background and objectives: EZH2 is overexpressed in hepatocellular carcinoma (HCC) and is correlated with poor prognosis. However, its clinical significance and molecular mechanism have not been studied in HCC. In this study, clinical and prognostic values of EZH2 was studied using Total Cancer Geno...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877936/ https://www.ncbi.nlm.nih.gov/pubmed/35208478 http://dx.doi.org/10.3390/medicina58020155 |
_version_ | 1784658534054494208 |
---|---|
author | Bae, An-Na Jung, Soo-Jung Lee, Jae-Ho Lee, Hyunsu Park, Seung Gyu |
author_facet | Bae, An-Na Jung, Soo-Jung Lee, Jae-Ho Lee, Hyunsu Park, Seung Gyu |
author_sort | Bae, An-Na |
collection | PubMed |
description | Background and objectives: EZH2 is overexpressed in hepatocellular carcinoma (HCC) and is correlated with poor prognosis. However, its clinical significance and molecular mechanism have not been studied in HCC. In this study, clinical and prognostic values of EZH2 was studied using Total Cancer Genome Atlas (TCGA) data and then, these data were confirmed in Huh1 and HepG2 cell lines. Materials and Methods: We used the TCGA database from cBioPortal. In addition, we analyzed EZH2 mRNA levels in HCC cell lines and its correlation with STAT3 and EZH2. Results: According to TCGA, EZH2 had a prognostic value in various cancers, especially in HCC. Furthermore, EZH2 in HCC was correlated with N stage (p = 0.045) and alpha-fetoprotein (AFP) > 20 ng/mL (p < 0.01). However, a negative association between EZH2 and age (p = 0.027) was found. The overall survival result of HCC was significantly poorer in patients with high EZH2 expression. In addition, the recurrence rate was also significantly higher in patients with high expression of EZH2 than those with low expression (χ2 = 16.10, p < 0.001). EZH2 expression was negatively correlated with STAT3 expression among EZH2-associated genes (R = −0.163, p = 0.002). EZH2 expression level was down-regulated to 50% or less compared to the control group treated negative siRNA. MTT assays showed that EZH2-siRNA affected on the viability of HCC cell line significantly. Conclusions: In conclusion, the overexpression of EZH2 was an independent biomarker for poor outcomes of HCC. However, more in vivo studies are required to identify the downstream target genes in HCC to improve our understanding of the biological role of EZH2 in HCC. |
format | Online Article Text |
id | pubmed-8877936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88779362022-02-26 Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy Bae, An-Na Jung, Soo-Jung Lee, Jae-Ho Lee, Hyunsu Park, Seung Gyu Medicina (Kaunas) Article Background and objectives: EZH2 is overexpressed in hepatocellular carcinoma (HCC) and is correlated with poor prognosis. However, its clinical significance and molecular mechanism have not been studied in HCC. In this study, clinical and prognostic values of EZH2 was studied using Total Cancer Genome Atlas (TCGA) data and then, these data were confirmed in Huh1 and HepG2 cell lines. Materials and Methods: We used the TCGA database from cBioPortal. In addition, we analyzed EZH2 mRNA levels in HCC cell lines and its correlation with STAT3 and EZH2. Results: According to TCGA, EZH2 had a prognostic value in various cancers, especially in HCC. Furthermore, EZH2 in HCC was correlated with N stage (p = 0.045) and alpha-fetoprotein (AFP) > 20 ng/mL (p < 0.01). However, a negative association between EZH2 and age (p = 0.027) was found. The overall survival result of HCC was significantly poorer in patients with high EZH2 expression. In addition, the recurrence rate was also significantly higher in patients with high expression of EZH2 than those with low expression (χ2 = 16.10, p < 0.001). EZH2 expression was negatively correlated with STAT3 expression among EZH2-associated genes (R = −0.163, p = 0.002). EZH2 expression level was down-regulated to 50% or less compared to the control group treated negative siRNA. MTT assays showed that EZH2-siRNA affected on the viability of HCC cell line significantly. Conclusions: In conclusion, the overexpression of EZH2 was an independent biomarker for poor outcomes of HCC. However, more in vivo studies are required to identify the downstream target genes in HCC to improve our understanding of the biological role of EZH2 in HCC. MDPI 2022-01-20 /pmc/articles/PMC8877936/ /pubmed/35208478 http://dx.doi.org/10.3390/medicina58020155 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bae, An-Na Jung, Soo-Jung Lee, Jae-Ho Lee, Hyunsu Park, Seung Gyu Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy |
title | Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy |
title_full | Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy |
title_fullStr | Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy |
title_full_unstemmed | Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy |
title_short | Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy |
title_sort | clinical value of ezh2 in hepatocellular carcinoma and its potential for target therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877936/ https://www.ncbi.nlm.nih.gov/pubmed/35208478 http://dx.doi.org/10.3390/medicina58020155 |
work_keys_str_mv | AT baeanna clinicalvalueofezh2inhepatocellularcarcinomaanditspotentialfortargettherapy AT jungsoojung clinicalvalueofezh2inhepatocellularcarcinomaanditspotentialfortargettherapy AT leejaeho clinicalvalueofezh2inhepatocellularcarcinomaanditspotentialfortargettherapy AT leehyunsu clinicalvalueofezh2inhepatocellularcarcinomaanditspotentialfortargettherapy AT parkseunggyu clinicalvalueofezh2inhepatocellularcarcinomaanditspotentialfortargettherapy |